Grant win for Lung Fibrosis Research
Our researchers are among a group of Australian scientists who have been awarded $2.5 million by the NHMRC to support a Centre for Research Excellence focusing on pulmonary fibrosis.
Pulmonary fibrosis is a group of lung diseases that are characterised by the build up of scar tissue in the lungs, which severely reduces the ability of the lung to expand and leads to significantly reduced lung function. This worsens as the disease progresses and impacts on every aspect of a patient’s life.
Idiopathic Pulmonary Fibrosis (IPF) is the most prevalent and devastating of all the lung fibrosis disorders and is life-threatening.
Through the IPF Registry, Dr Svetlana Baltic will lead a national biobank, where samples from IPF patients will be collected Australia wide and stored at the Institute. The samples will identify biomarkers for IPF diagnosis, prognosis and a response to therapy. Importantly, the samples will also be available to other medical researchers in the field.
The development of a Centre of Research Excellence focusing on pulmonary fibrosis provides the unique opportunity to both identify ways of targeting this incurable condition as well as provide the much needed support for patients and the training of future clinicians.
The Centre brings together a team of world leading scientists and clinicians across Australia who together, will develop strategies to better manage pulmonary fibrosis.
The team, headed by Associate Professor Tamera Corte from the University of Sydney, will deliver public education and clinical training programs as well as develop a comprehensive and integrated national research program into the epidemiology of lung fibrosis.
This research effort is supported by existing collaborative clinical and research platforms; the Australian IPF registry, the IPF Blood Biobank and the Pulmonary Fibrosis Lung Tissue Bank.
It also adds to our existing, NHMRC funded lung fibrosis research program.